January 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable electronic injector designed to enhance the administration of injectable medications while helping partners meet their sustainability goals.
Cambridge, MA. - January 7, 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable injector designed to enhance the administration of injectable medications. Built on Portal’s robust platform technology, the PRIME Nexus is a needle-based device designed to be compatible with standard primary containers, including 1mL pre-filled syringes (PFS), 2.25mL PFS, and 3mL cartridges.
The PRIME Nexus represents a significant advancement in drug delivery, offering precise control and versatility for a wide range of therapies. This innovative device is poised to be a game-changer for pharmaceutical companies and patients alike, offering several key advantages:
The PRIME Nexus is designed to seamlessly integrate into existing manufacturing and packaging processes, streamlining the development and commercialization of new injectable therapies. Its compatibility with standard primary containers further simplifies integration and reduces development timelines.
Portal Instruments will showcase the PRIME Nexus device at Pharmapack and other key industry events. Attendees will have the opportunity to see the device in action and discuss feasibility or development studies for this reusable injector.
About Portal Instruments:
Portal Instruments is a privately held medical device company focused on developing and commercializing innovative drug delivery platform technologies to transform the administration of injectable medications. Portal's goal is to improve patient experience, adherence, and outcomes by providing advanced delivery solutions.
January 18, 2022 - Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated self-injection options...
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Please fill out the details below and we will get back to you shortly.